These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21648224)

  • 21. Everolimus and pazopanib: two new drugs for renal cell cancer.
    Med Lett Drugs Ther; 2010 May; 52(1337):33-4. PubMed ID: 20431519
    [No Abstract]   [Full Text] [Related]  

  • 22. Imatinib and inoperable or metastatic gastrointestinal stromal tumours. Longer follow-up confirms the overall survival benefit.
    Prescrire Int; 2011 Mar; 20(114):61-3. PubMed ID: 21648223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pazopanib: in advanced renal cell carcinoma.
    Sanford M; Keating GM
    BioDrugs; 2010 Oct; 24(5):279-86. PubMed ID: 20649181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pazopanib and soft-tissue sarcomas. Too toxic.
    Prescrire Int; 2013 Jun; 22(139):145-7. PubMed ID: 23866345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.
    Xu CF; Bing NX; Ball HA; Rajagopalan D; Sternberg CN; Hutson TE; de Souza P; Xue ZG; McCann L; King KS; Ragone LJ; Whittaker JC; Spraggs CF; Cardon LR; Mooser VE; Pandite LN
    J Clin Oncol; 2011 Jun; 29(18):2557-64. PubMed ID: 21576632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pazopanib: a review of its use in the management of advanced renal cell carcinoma.
    McCormack PL
    Drugs; 2014 Jul; 74(10):1111-25. PubMed ID: 24935162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pazopanib in renal cell carcinoma.
    Sternberg CN
    Clin Adv Hematol Oncol; 2010 Apr; 8(4):232-3. PubMed ID: 20505644
    [No Abstract]   [Full Text] [Related]  

  • 28. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.
    Friedlander M; Hancock KC; Rischin D; Messing MJ; Stringer CA; Matthys GM; Ma B; Hodge JP; Lager JJ
    Gynecol Oncol; 2010 Oct; 119(1):32-7. PubMed ID: 20584542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pazopanib, a new therapy for metastatic soft tissue sarcoma.
    Verweij J; Sleijfer S
    Expert Opin Pharmacother; 2013 May; 14(7):929-35. PubMed ID: 23488774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incorporation of pazopanib in maintenance therapy of ovarian cancer.
    du Bois A; Floquet A; Kim JW; Rau J; del Campo JM; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Kimmig R; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Mouret-Reynier MA; Kim JH; Kurzeder C; Lesoin A; Vasey P; Marth C; Canzler U; Scambia G; Shimada M; Calvert P; Pujade-Lauraine E; Kim BG; Herzog TJ; Mitrica I; Schade-Brittinger C; Wang Q; Crescenzo R; Harter P
    J Clin Oncol; 2014 Oct; 32(30):3374-82. PubMed ID: 25225436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
    Brotelle T; Bay JO
    Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
    Sternberg CN; Davis ID; Deen KC; Sigal E; Hawkins RE
    Oncology; 2014; 87(6):342-50. PubMed ID: 25227656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors.
    Goh BC; Reddy NJ; Dandamudi UB; Laubscher KH; Peckham T; Hodge JP; Suttle AB; Arumugham T; Xu Y; Xu CF; Lager J; Dar MM; Lewis LD
    Clin Pharmacol Ther; 2010 Nov; 88(5):652-9. PubMed ID: 20881954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nursing considerations for patients receiving pazopanib for renal cell carcinoma.
    Becze E
    ONS Connect; 2012 Feb; 27(2):16-7. PubMed ID: 22375508
    [No Abstract]   [Full Text] [Related]  

  • 35. Pazopanib: a new multiple tyrosine kinase inhibitor in the therapy of metastatic renal cell carcinoma and other solid tumors.
    Melichar B; Studentová H; Zezulová M
    J BUON; 2011; 16(2):203-9. PubMed ID: 21766486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pazopanib (Votrient) in the management of renal cell cancer and soft tissue sarcomas].
    Gennigens C; Jerusalem G
    Rev Med Liege; 2012; 67(7-8):437-42. PubMed ID: 22984765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacological sheet: pazopanib (Votrient), oral administration].
    J Pharm Belg; 2011 Sep; (3):95-6. PubMed ID: 21995103
    [No Abstract]   [Full Text] [Related]  

  • 38. Pazopanib.
    Bukowski RM; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2010 Jan; 9(1):17-8. PubMed ID: 20043026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
    Boudou-Rouquette P; Tlemsani C; Blanchet B; Huillard O; Jouinot A; Arrondeau J; Thomas-Schoemann A; Vidal M; Alexandre J; Goldwasser F
    Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1433-1444. PubMed ID: 27556889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib.
    Jacobs C; Kim DW; Straka C; Timmerman RD; Brugarolas J
    J Clin Oncol; 2013 Mar; 31(7):e114-7. PubMed ID: 23319695
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.